Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

1.

Advances in Modeling Model Discrepancy: Comment on Wu and Browne (2015).

MacCallum RC, O'Hagan A.

Psychometrika. 2015 Mar 27. [Epub ahead of print]

PMID:
25813464
2.

Robust meta-analytic-predictive priors in clinical trials with historical control information.

Schmidli H, Gsteiger S, Roychoudhury S, O'Hagan A, Spiegelhalter D, Neuenschwander B.

Biometrics. 2014 Dec;70(4):1023-32. doi: 10.1111/biom.12242. Epub 2014 Oct 29.

PMID:
25355546
3.

Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.

Ouellet D, Gibiansky E, Leonowens C, O'Hagan A, Haney P, Switzky J, Goodman VL.

J Clin Pharmacol. 2014 Jun;54(6):696-706. doi: 10.1002/jcph.263. Epub 2014 Jan 17.

PMID:
24408395
4.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U.

J Clin Oncol. 2013 Sep 10;31(26):3205-11. doi: 10.1200/JCO.2013.49.8691. Epub 2013 Aug 5.

5.

Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.

Griffiths RI, Gleeson ML, Danese MD, O'Hagan A.

Value Health. 2012 Jul-Aug;15(5):656-63. doi: 10.1016/j.jval.2012.03.1388. Epub 2012 Jun 22.

PMID:
22867774
6.

Trends in skin cancer knowledge, sun protection practices and behaviours in the Northern Ireland population.

Gavin A, Boyle R, Donnelly D, Donnelly C, Gordon S, McElwee G, O'Hagan A.

Eur J Public Health. 2012 Jun;22(3):408-12. doi: 10.1093/eurpub/ckr087. Epub 2011 Nov 16.

7.

Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.

Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH.

Pharmacoeconomics. 2012 Feb 1;30(2):103-18. doi: 10.2165/11589440-000000000-00000.

PMID:
21967155
8.

Designing a non-inferiority study in kidney transplantation: a case study.

Witte S, Schmidli H, O'Hagan A, Racine A.

Pharm Stat. 2011 Sep-Oct;10(5):427-32. doi: 10.1002/pst.511. Epub 2011 Sep 16.

PMID:
21928323
9.

Review of statistical methods for analysing healthcare resources and costs.

Mihaylova B, Briggs A, O'Hagan A, Thompson SG.

Health Econ. 2011 Aug;20(8):897-916. doi: 10.1002/hec.1653. Epub 2010 Aug 27. Review.

10.

Trends in reported sun bed use, sunburn, and sun care knowledge and attitudes in a U.K. region: results of a survey of the Northern Ireland population.

Boyle R, O'Hagan AH, Donnelly D, Donnelly C, Gordon S, McElwee G, Gavin A.

Br J Dermatol. 2010 Dec;163(6):1269-75. doi: 10.1111/j.1365-2133.2010.09977.x. Epub 2010 Sep 30.

PMID:
20716213
11.

A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method.

Kharroubi SA, O'Hagan A, Brazier JE.

Stat Med. 2010 Jul 10;29(15):1622-34. doi: 10.1002/sim.3874.

PMID:
20209481
12.

Public at risk: a survey of sunbed parlour operating practices in Northern Ireland.

Gavin A, Donnelly C, Devlin A, Devereux C, O'Callaghan G, McElwee G, Gordon S, Crossan T, McMahon N, Loan P, Martin S, McPeak L, Caughey J, O'Hagan AH.

Br J Dermatol. 2010 Mar;162(3):627-32. doi: 10.1111/j.1365-2133.2009.09591.x. Epub 2009 Nov 18.

PMID:
19922531
13.

The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.

Nixon RM, O'Hagan A, Oakley J, Madan J, Stevens JW, Bansback N, Brennan A.

Pharm Stat. 2009 Oct-Dec;8(4):371-89. doi: 10.1002/pst.368.

PMID:
19340851
14.

The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.

Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, Boggild M, Palace J, Ebers G, Chilcott JB, Tappenden P, Nicholl J.

BMC Neurol. 2009 Jan 6;9:1. doi: 10.1186/1471-2377-9-1.

15.

Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement.

McCabe C, Claxton K, O'Hagan A.

Int J Technol Assess Health Care. 2008 Spring;24(2):140-5. doi: 10.1017/S0266462308080197.

PMID:
18400115
16.

Calculating partial expected value of perfect information via Monte Carlo sampling algorithms.

Brennan A, Kharroubi S, O'hagan A, Chilcott J.

Med Decis Making. 2007 Jul-Aug;27(4):448-70.

PMID:
17761960
17.
18.

Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method.

Kharroubi S, Brazier JE, O'Hagan A.

Soc Sci Med. 2007 Mar;64(6):1242-52. Epub 2006 Dec 8.

PMID:
17157971
19.

Modelling SF-6D health state preference data using a nonparametric Bayesian method.

Kharroubi SA, Brazier JE, Roberts J, O'Hagan A.

J Health Econ. 2007 May 1;26(3):597-612. Epub 2006 Oct 27.

PMID:
17069909
20.

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.

Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D.

Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk